Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines - PubMed (original) (raw)
Affiliations
- PMID: 1694291
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
J Bartek et al. Oncogene. 1990 Jun.
Abstract
The expression of the tumour suppressor gene p53 was analysed in 11 human breast cancer cell lines by immunohistochemistry, immunoprecipitation and cDNA sequencing. We used a panel of anti-p53 monoclonal antibodies for cell staining and found abnormalities in every case. Eight of the cell lines produce a form of p53 which can be immunoprecipitated by the monoclonal antibody PAb240 but not by PAb1620. In the murine system PAb240 only immunoprecipitates mutant p53. We sequenced p53 cDNA directly from four of the PAb240 positive cell lines using asymmetric PCR templates. All four contained missense mutations in p53 RNA, with no detectable expression of the wild type sequence. Different residues were affected in each cell line, but all the mutations changed amino acids conserved from man to Xenopus. These results imply that as in the murine system, the PAb240 antibody reliably detects a wide variety of p53 mutations and that these mutations have a common effect on the structure of p53. Immunohistochemical data suggest that p53 mutation is the commonest genetic alteration so far detected in primary breast cancer.
Similar articles
- Maintenance of p53 alterations throughout breast cancer progression.
Davidoff AM, Kerns BJ, Iglehart JD, Marks JR. Davidoff AM, et al. Cancer Res. 1991 May 15;51(10):2605-10. Cancer Res. 1991. PMID: 1850660 - Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.
Takahashi T, D'Amico D, Chiba I, Buchhagen DL, Minna JD. Takahashi T, et al. J Clin Invest. 1990 Jul;86(1):363-9. doi: 10.1172/JCI114710. J Clin Invest. 1990. PMID: 2164047 Free PMC article. - Expression of p53 and 17p allelic loss in colorectal carcinoma.
Cunningham J, Lust JA, Schaid DJ, Bren GD, Carpenter HA, Rizza E, Kovach JS, Thibodeau SN. Cunningham J, et al. Cancer Res. 1992 Apr 1;52(7):1974-80. Cancer Res. 1992. PMID: 1551126 - p53: oncogene or anti-oncogene?
Lane DP, Benchimol S. Lane DP, et al. Genes Dev. 1990 Jan;4(1):1-8. doi: 10.1101/gad.4.1.1. Genes Dev. 1990. PMID: 2137806 Review. No abstract available. - Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products.
Levine AJ, Momand J. Levine AJ, et al. Biochim Biophys Acta. 1990 Jun 1;1032(1):119-36. doi: 10.1016/0304-419x(90)90015-s. Biochim Biophys Acta. 1990. PMID: 2142001 Review. No abstract available.
Cited by
- Pyrimidine Triones as Potential Activators of p53 Mutants.
Fallatah MMJ, Demir Ö, Law F, Lauinger L, Baronio R, Hall L, Bournique E, Srivastava A, Metzen LT, Norman Z, Buisson R, Amaro RE, Kaiser P. Fallatah MMJ, et al. Biomolecules. 2024 Aug 8;14(8):967. doi: 10.3390/biom14080967. Biomolecules. 2024. PMID: 39199355 Free PMC article. - Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions.
Naeimzadeh Y, Tajbakhsh A, Fallahi J. Naeimzadeh Y, et al. Heliyon. 2024 Feb 10;10(4):e26260. doi: 10.1016/j.heliyon.2024.e26260. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38390040 Free PMC article. Review. - HetFCM: functional co-module discovery by heterogeneous network co-clustering.
Tan H, Guo M, Chen J, Wang J, Yu G. Tan H, et al. Nucleic Acids Res. 2024 Feb 9;52(3):e16. doi: 10.1093/nar/gkad1174. Nucleic Acids Res. 2024. PMID: 38088228 Free PMC article. - Biological Effects of HDAC Inhibitors Vary with Zinc Binding Group: Differential Effects on Zinc Bioavailability, ROS Production, and R175H p53 Mutant Protein Reactivation.
Flores BM, Uppalapati CK, Pascual AS, Vong A, Baatz MA, Harrison AM, Leyva KJ, Hull EE. Flores BM, et al. Biomolecules. 2023 Oct 28;13(11):1588. doi: 10.3390/biom13111588. Biomolecules. 2023. PMID: 38002270 Free PMC article. - Generation of precision preclinical cancer models using regulated in vivo base editing.
Katti A, Vega-Pérez A, Foronda M, Zimmerman J, Zafra MP, Granowsky E, Goswami S, Gardner EE, Diaz BJ, Simon JM, Wuest A, Luan W, Fernandez MTC, Kadina AP, Walker JA 2nd, Holden K, Lowe SW, Sánchez Rivera FJ, Dow LE. Katti A, et al. Nat Biotechnol. 2024 Mar;42(3):437-447. doi: 10.1038/s41587-023-01900-x. Epub 2023 Aug 10. Nat Biotechnol. 2024. PMID: 37563300 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous